secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tengjun Biotechnology Corp. (—)
CIK:        0001499785
Form:       8-K/A
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001213900-23-078373
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tengjun Biotechnology restates FY2022 financials; appoints interim CEO/CFO after death of prior officer
--------------------------------------------------------------------------------

- Board concludes FY2022 10-K financials should no longer be relied upon due to accounting methodology errors.
- Auditor PWN LLP discovered discrepancies during Q2 review; errors include accounting policies and estimates.
- Company to restate FY2022 financials; transition from manual to automated accounting system identified discrepancies.
- Caihong Qu appointed as director, interim CEO and CFO effective August 10, 2023, replacing Xianchang Ma (deceased).
- PWN LLP agrees with the company's statements in the Form 8-K/A filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/0001213900-23-078373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/ea185571-8ka2_tengjun.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-078373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer